21. Pyrimidine Metabolism

Focused on the synthesis, regulation, catabolism, chemotherapeutics, and genetic disorders related to pyrimidine metabolism.

Describe de novo and salvage synthesis of pyrimidine ribonucleotides and their regulation.
Explain pyrimidine catabolism.
Discuss chemotherapeutic agents related to pyrimidines.
Explore genetic disorders linked with pyrimidine metabolism.

Precursor Sources: Begins with carbon (C) and nitrogen (N) sources.
Function: To produce pyrimidine nucleotides (Thymine [T], Cytosine [C] for DNA; Uracil [U], Cytosine [C] for RNA).
Location: Occurs in the cytoplasm of most cells.
Amino Acid Requirement: Relies on amino acids like glutamine and aspartate.
Regulation: UTP inhibits the synthesis of carbamoyl phosphate, which is vital for the process.
Key Difference from Purines: Pyrimidine ring is synthesized first, then attached to PRPP (5-phosphoribosyl-1-pyrophosphate), whereas purine rings are built directly on PRPP.

N-Glycosidic Bond Formation: In purine synthesis, the bond is formed early; in pyrimidine synthesis, the ring is fully synthesized before it attaches to the ribose-5-phosphate.
Key Intermediate: Orotic acid acts as a precursor that contains the pyrimidine structure.
De Novo Synthesis Requirements: Requires ATP hydrolysis and utilizes amino acids as starting materials.

De Novo Pathway: Involves creating the nucleotide from scratch using simpler components (bicarbonate, aspartic acid, ammonia).
Salvage Pathway: Reattaching bases to a ribose backbone, utilizing PRPP to regenerate nucleotides from free bases.

Carbamoyl Phosphate Formation: Initiates the pathway; involves ATP and ammonia.
Carbamoyl Aspartate Formation: CPS II regulated by UTP and ATP levels.
Dihydroorotate Formation: Oxidation steps to stabilize the pyrimidine.
Ornithine Decarboxylation: Contributes to nucleotide structure.
Formation of OMP (Orotidine Monophosphate): Key intermediate.
Decarboxylation: OMP is transformed into UMP.
Phosphorylation Stages: UMP to UDP (using monophosphate kinase) and UDP to UTP (using diphosphate kinase).
Formation of CTP: By adding amino groups from glutamine using CTP synthetase.

CPS II Control: Key regulatory enzyme, influenced by UTP and PRPP levels.
Feedback Inhibition: Increased levels of pyrimidines reduce CPS II activity.
Cell Cycle Influence: S-phase alters CPS II sensitivity to available substrates.

Type 1 Pathway: Involves attaching the pyrimidine base to PRPP forming monophosphates.
Type 2 Pathway: Attaching bases to ribose 1-phosphate; provides flexibility in creating nucleotides from existing bases.
Key Enzymes: Include pyrimidine phosphoribosyl transferase and kinases specific to nucleoside conversions.

Breakdown of pyrimidine nucleotides leads to the production of soluble compounds (e.g., β-alanine, β-aminoisobutyric acid).
Process: Nucleotides become nucleosides via phosphatases, further degraded to bases and carbon skeletons eventually leading to CO2 and ammonia.

Methotrexate (MTX): Folic acid analog that inhibits dihydrofolate reductase impacting nucleotide synthesis.
Pyrimidine Analogs: 5-fluorouracil and others that inhibit thymidylate synthetase useful in cancer treatments.

Orotic Aciduria: Linked to enzyme deficiencies (orotate phosphoribosyl transferase, OMP decarboxylase) leading to excessive orotate excretion and megaloblastic anemia.
Symptoms: Growth retardation, urinary crystals, treatable by dietary uridine or cytidine for feedback inhibition.

Pyrimidine metabolism encompasses complex synthesis, regulation, and catabolism processes with significant clinical implications through biochemical pathways. Understanding these pathways aids in diagnosing and treating related disorders effectively.